FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Fenimo (Last)	ore Christ	Reporting Person* opher R.  irst) LL RIVER ROA	- RE IN 3. D	Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS,      INC. [ REGN ]      Date of Earliest Transaction (Month/Day/Year) 04/01/2020									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title below)  VP Controller						
(Street) TARRY	TOWN N	Y	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)     6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting												n			
(City)	(S	tate)	(Zip)												Persoi	1			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					nd 5)	Securiti Benefic Owned Reporte	5. Amount of Securities Beneficially Owned Following Reported		Direct of Indirect Etr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	٧	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				
Common	Stock			04/01/	2020	)20			<b>M</b> <sup>(1)</sup>		1,200	A	\$30.63		14	1,297		D	
Common	Stock			04/01/	2020	)20			S <sup>(1)</sup>		63	D	\$478.77		14	4,234		D	
Common	Stock			04/01/	2020	)20			S <sup>(1)</sup>		69	D	\$479		14	4,165		D	
Common	Stock			04/01/	04/01/2020						58	D	\$480.28		14	4,107		D	
Common	Stock			04/01/	04/01/2020				S <sup>(1)</sup>		62	D	\$482.09		14	4,045		D	
Common	Stock			04/01/	04/01/2020				S <sup>(1)</sup>		124	D	\$483.58(2)		13	3,921		D	
Common Stock 04/01/					2020				S <sup>(1)</sup>		3	D	\$484.14		13	3,918		D	
Common	Stock			04/01/	2020				S <sup>(1)</sup>		137	D	\$488	3.76 <sup>(3)</sup>	13	,781		D	
Common	Stock			04/01/	2020				S <sup>(1)</sup>		201	D	\$489	).48 <sup>(4)</sup>	13	,580		D	
Common Stock 04/01/2					2020				S <sup>(1)</sup>		70	D	\$49	1.65	13	,510		D	
Common Stock (				04/01/			S <sup>(1)</sup>		134	D	\$492.45(5)		13	3,376		D			
Common Stock			04/01/			S <sup>(1)</sup>		174	D	\$493.24(6)		13	3,202		D				
Common Stock			04/01/			S <sup>(1)</sup>		37	D	\$494.16		13	13,165		D				
Common Stock 0			04/01/	04/01/2020						68	D	\$497.99		13	13,097		D		
Common Stock														1,	1,401		I 4	3y 401(k) Plan	
Common Stock													1,	,897			Зу Гrust <sup>(7)</sup>		
Common Stock														5	509			oy 2017 GRAT	
Common Stock														2,284				oy 2018 GRAT	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed 4. Execution Date, Unrity or Exercise (Month/Day/Year) if any Coc			4. Transa Code (l	saction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Exerci	isable and te	7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Pr Deriv Secu (Inst	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly G	10. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numl of Share	ber					
Incentive Stock Option (right to buy)	\$30.63	04/01/2020			M <sup>(1)</sup>			1,200	(8)		12/14/2020	Common Stock	1,20	00	\$0.0	2,180		D	

## Explanation of Responses:

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- 2. Represents volume-weighted average price of sales of 124 shares of Company stock on April 1, 2020 at prices ranging from \$483.35 to \$483.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price.
- 3. Represents volume-weighted average price of sales of 137 shares of Company stock on April 1, 2020 at prices ranging from \$488.57 to \$488.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price.
- 4. Represents volume-weighted average price of sales of 201 shares of Company stock on April 1, 2020 at prices ranging from \$489.17 to \$489.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price.
- 5. Represents volume-weighted average price of sales of 134 shares of Company stock on April 1, 2020 at prices ranging from \$492.07 to \$492.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price.
- 6. Represents volume-weighted average price of sales of 174 shares of Company stock on April 1, 2020 at prices ranging from \$493.14 to \$493.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price.
- 7. These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
- 8. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

/s/\*\*Christopher R. Fenimore 04/02/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.